News
-
-
PRESS RELEASE
BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. initiates nationalization process for sublingual anticancer drug patents for autoimmune neurodegenerative diseases. Positive report from European Patent Office on patentability -
-
PRESS RELEASE
Terry Lynch Joins BioNxt as Capital Markets Advisor
BioNxt Solutions Inc. appoints Terry Lynch, a capital markets advisor with extensive experience in resource and bioscience sectors. Mr. Lynch joins the team to support the development and commercialization of the sublingual Cladribine product for MS treatment -
-
PRESS RELEASE
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
BioNxt Solutions Inc. updates on sublingual Cladribine drug formulation program for Multiple Sclerosis, patent applications, and investor relations activities. Company aims to revolutionize drug delivery systems for CNS diseases -
-
PRESS RELEASE
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. receives positive international examination report from the European Patent Office for sublingual delivery patent application. Company to expand patent portfolio for neurodegenerative diseases and MS market -
-
